- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Soleno Therapeutics Faces Class Action Lawsuit
ClaimsFiler Reminds Investors of Lead Plaintiff Deadline in Lawsuit Against Soleno Therapeutics
Mar. 19, 2026 at 3:05am
Got story updates? Submit your updates here. ›
ClaimsFiler, a shareholder information service, has reminded investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. The lawsuit alleges that Soleno failed to disclose material information during the Class Period from March 26, 2025 to November 4, 2025, violating federal securities laws.
Why it matters
The lawsuit claims that Soleno, a pharmaceutical company, systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its only commercial product, DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome. This could have significant implications for the company's commercial viability and future prospects.
The details
The lawsuit alleges that Soleno failed to disclose that the administration of DCCR posed materially greater safety risks than disclosed, including indications of excessive fluid retention among clinical trial participants. As a result, the company's lead product candidate had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch.
- The Class Period for the lawsuit is from March 26, 2025 to November 4, 2025.
- The lead plaintiff deadline is May 5, 2026.
The players
Soleno Therapeutics, Inc.
A pharmaceutical company that is the defendant in the class action lawsuit.
ClaimsFiler
A shareholder information service that is reminding investors of the lead plaintiff deadline in the class action lawsuit against Soleno Therapeutics.
Kahn Swick & Foti, LLC
The law firm that is available to discuss legal options for Soleno investors.
What’s next
The judge in the case will decide on May 5, 2026 whether to allow the lawsuit to proceed as a class action.
The takeaway
This lawsuit highlights the importance of pharmaceutical companies fully disclosing potential safety concerns associated with their products, as failure to do so can have significant legal and financial consequences.
